TRDA · CIK 0001689375
What Entrada Therapeutics, Inc. told the SEC could break it.
As a pre-product company, Entrada's revenue rests almost entirely on one relationship: substantially all of its revenue to date has come from its Vertex collaboration (VX-670), so any change to that agreement would remove essentially all of its current income. Its supply chain is the other concentration. It, its collaborators and the third parties it relies on depend on China-based suppliers and service providers for certain raw materials, products and preclinical/clinical services, exposing it to U.S.-China trade restrictions, tariffs and NDAA-type rules. And one or more of its programs may have a single source for raw materials and excipients, where an interruption could delay clinical and commercial supply and qualifying a replacement would take time and regulatory approval.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- substantially all revenue from the Vertex Agreementhigh
Substantially all of Entrada's revenue to date derives from a single collaboration — the Vertex Agreement (VX-670); any change to that agreement would remove essentially all current revenue for the pre-product company.
“Substantially all of our revenue to date has been derived from the Vertex Agreement.”
SEC filing →As of 2026
Regulatory & policy
- China-based supplier dependence & US-China trade restrictions (NDAA)medium
Entrada and its collaborators/third parties rely on China-based suppliers and service providers for certain raw materials, products and preclinical/clinical services; US-China geopolitical developments, tariffs and NDAA-type restrictions could limit access and raise costs.
“the pharmaceutical industry generally, and in some instances our Company, our collaborators or other third parties on which we rely, depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities.”
SEC filing →As of 2026
Sole-source dependency
- single-source raw materials & excipientsmedium
One or more Entrada programs may have a single source of supply for raw materials and excipients; an interruption could delay clinical and commercial supply, and qualifying a replacement supplier would require time and regulatory approval.
“Further, now and in the future one or more of our programs may have a single source of supply for raw materials and excipients.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Vertex Pharmaceuticals Incorporated
“Substantially all of our revenue to date has been derived from the Vertex Agreement.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch